摘要
采用链霉亲和素过氧化酶免疫组织化学方法 (S -P法 )检测 30例初发成人急性髓系白血病(AML)患者的骨髓细胞bcl - 2蛋白表达 .结果 :( 1)AML患者骨髓细胞中bcl - 2蛋白阳性表达率为( 55 12± 2 3 78) % ( 19%～ 93% ) ,显著高于正常对照 (P <0 0 1) . ( 2 )AML按FAB分型各亚型间比较 :bcl- 2蛋白表达在M1,M2 型阳性率较高 ( 60 58± 19 0 5) % ;M3 型则较低 ( 2 1 50± 6 2 2 ) % ;M4 ,M5型最高( 69 64± 14 96) % . ( 3)经标准诱导治疗后 ,完全缓解 (CR)组的bcl- 2蛋白表达显著低于未缓解 (NR)组 (P <0 0 5) .提示 :bcl- 2蛋白在AML细胞中呈高表达 ,并为白血病化疗耐药的预后指标之一 .
By means of Streptavidin-Peroxidase immunohistochemical staining assay, the expression of bc1-2 gene was investigated in 30 patients with acute myeloid leukemia(AML). The results showed: (1) The percentage of bc1-2 + cells in AML was 55 12% ±23 78% ( range, 19% to 93%), which was significantly higher than those in control( P <0 01). (2) According to French-American-British classification, the percentage of bc1-2+cells was higher in M1 and M2 types (60 58% ±19 05%), lower in M3 (21 50%± 6 22%) and the highest in M4 and M5 types( 69 64% ± 14 96%).(3) After the standard inducing therapy of AML, bcl-2 expression in complete remission group was obviously lower than that in resistant disease group( P <0 01). We conclude that bcl-2 expression in AML is higher than that in normal human myeloid cells. High expression of be1-2 is associated with a low complete remission rate after intensive chemotherapy.
出处
《昆明医学院学报》
2000年第2期51-52,80,共3页
Journal of Kunming Medical College
基金
云南省应用基础研究基金资助项目!(95C139M)
